Outcome of Treatment of CML with 2(nd) Generation Tyrosine Kinase Inhibitors After Imatinib Failure

Παρόμοια τεκμήρια

• Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm
  ανά: Jabbour, Elias, κ.ά.
  Έκδοση: (2015)
• Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
  ανά: Jabbour, Elias, κ.ά.
  Έκδοση: (2011)
• Long-Term Outcomes in the Second-Line Treatment of Chronic Myeloid Leukemia: A Review of Tyrosine Kinase Inhibitors
  ανά: Jabbour, Elias, κ.ά.
  Έκδοση: (2010)
• Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
  ανά: Jabbour, Elias, κ.ά.
  Έκδοση: (2009)
• Molecular Monitoring in Chronic Myeloid Leukemia: Response to Tyrosine Kinase Inhibitors and Prognostic Implications
  ανά: Jabbour, Elias, κ.ά.
  Έκδοση: (2008)